Table 2 Genes from the best COXEN models for predicting clinical response to doxorubicin and carboplatin in the COS33
From: Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma
Model | Gene symbol | Gene title | Function |
|---|---|---|---|
Doxorubicin model NCI60-COS16-COS16-COS33 | CHKA | Choline kinase alpha | Phospholipid biosynthesis, tumor cell growth |
TLE1 | Transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) | Transcriptional co-repressor; inhibits NF-kappa-B expression and WNT signaling | |
EIF6 | Eukaryotic translation initiation factor 6 | Helps ITGBB4 link to cytoskeleton | |
TES | Testis derived transcript (3 LIM domains) | Scaffold protein; role in cell adhesion, cell spreading, reorganization of actin cytoskeleton, regulates cell proliferation, may act as a tumor suppressor | |
Carboplatin model FACC-COS16-FACC-COS33 | OCA2 | Oculocutaneous albinism II | Transporter of tyrosine within the melanocyte, may determine eye and skin color |
HES3 | Hairy and enhancer of split 3 (Drosophila) | Transcriptional repressor of genes that require bHLH protein for their transcription | |
LOC100688725 | Uncharacterized Cytochrome C oxidase | Cytochrome C oxidase activity | |
PSMD3 | Proteasome (prosome, macropain) 26 s subunit, non-ATPase, 3 | Involved in ATP-dependent degradation of ubiquinated proteins | |
cOR4F25 | cOR4F25 olfactory receptor family 4 subfamily F-like | Involved in canine olfactory system | |
KIAA0922 | Transmembrane protein 131-like | Integral transmembrane protein, possible involvement in immune responses |